BYSI News and Press, BeyondSpring Inc. From 04/14/22

NEW YORK, April 14, 2022 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a clinical stage global biopharmaceutical company focused on developing innovative cancer therapies to improve clinical outcomes for patients who ...

BeyondSpring press release (NASDAQ:BYSI): FY GAAP EPS of -$1.64 beats by $0.02. Revenue of $1.35M (+650.0% Y/Y) misses by $7.22M. Cash, cash equivalents, and short-term investments of $72.4M. The company believes it has sufficient cash to support its ongoing operations and clinical progr...

- Company to host call today, April 14, 2022 at 8:00 am ET - Conference call can be accessed by dialing 877-451-6152 (U.S. and Canada) or +1-201-389-0879 (International). The passcode is 13728822. The live webcast can be accessed here or by visiting the “...

BeyondSpring (NASDAQ:BYSI) Q421 consensus EPS estimate is -$0.25, compared to -$0.79 a year ago, and consensus revenue estimate is $7.63M, compared to $337.00K. Over the last 3 months, the company's EPS and revenue estimates have seen 1 upward revision and 0 downward ...

ALLY, BYSI, C, CBAT, ERIC, GS, MS, PGR, PNC, RAD, STT, TNP, TSM, UNH, USB, WFC For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Thursday's open

NEW YORK, April 08, 2022 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it will report its financial re...

BeyondSpring Inc. (NASDAQ:BYSI) traded at a new 52-week high today of $48.03. Approximately 43.5 million shares have changed hands today, as compared to an average 30-day volume of 376,000 shares. BeyondSpring Inc is engaged in clinical stage biopharmaceutical activities focused on the d...

A spate of bad luck has destroyed SPPI stock. CEO and CFO have both resigned. Even if, somehow, ROLONTIS gets approved, they don't have the cash to commercialize. For further details see: Spectrum Pharmaceuticals: Some Last Words

BYSI was handed a CRL last year. NSCLC data has also been called into question. The future looks bleak. For further details see: BeyondSpring, Beyond Salvage

Resources to be Focused on Highest Value Business Activities 35% Reduction in Workforce in the U.S. Implemented to Preserve Long-Term Sustainability NEW YORK, Jan. 11, 2022 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals (the “Company” or “...